Nitric oxide is not a mediator of inflammation-induced to atracurium

Anesthesia and Analgesia

Volumn 101, Issue 5, 2005, Pages 1362-1367

  Fink, Heidrun ^a,c   Bogdanski, Ralph ^a   Luppa, Peter ^b   Martyn, J A Jeevendra ^c   Blobner, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ATRACURIUM; CHOLINERGIC RECEPTOR; FENTANYL; N IMINOLYSINE; NEUROMUSCULAR BLOCKING AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROUS OXIDE; OROSOMUCOID; PROPOFOL; SEVOFLURANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

EID: 27444434721     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000180832.62367.CC     Document Type: Article

References (16)

1. Henderson JL, Statman R, Cunningham JN, et al. The effects of nitric oxide inhibition on regional hemodynamics during hyperdynamic endotoxemia. Arch Surg 1994;129:1271-4.
2. Iskit AB, Guc O. Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia, and survival in experimental models of septic shock. Acta Pharmacol Sin 2003;24:953-7.
3. Veihelmann A, Brill T, Blobner M, et al. Inhibition of nitric oxide synthases improves detoxication in inflammatory liver dysfunction in vivo. Am J Physiol 1997;273:G530-6.
4. Fink H, Luppa P, Mayer B, et al. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors. Anesthesiology 2003;98:82-8.
5. Blobner M, Kochs E, Fink H, et al. Pharmacokinetics and pharmacodynamics of vecuronium in rats with systemic inflammatory response syndrome: treatment with N(G)-monomethyl-L-arginine. Anesthesiology 1999;91:999-1005.
6. Archer S. Measurement of nitric oxide in biological models. FASEB J 1993;7:349-60.
7. Metzger J, Blobner M, Luppa PB. Sensitive chemiluminescence immunoassay for the determination of rat serum alpha1-acid glycoprotein. Clin Chem Lab Med 2001;39:514-8.
8. Ibebunjo C, Martyn JA. Fiber atrophy, but not changes in acetylcholine receptor expression, contributes to the muscle dysfunction after immobilization. Crit Care Med 1999;27:275-85.
9. Scheller M, Blobner M, Von Loewenich C, et al. The NO synthase inhibitors L-Name and L-NMMA, but not L-arginine, block the mammalian nicotinic acetylcholine receptor channel. Toxicol Lett 1998;100-101:109-13.
10. Blobner M, Stadler J, Brill T, et al. Pharmacodynamics of atracurium and vecuronium in rats with inflammatory liver dysfunction - treatment with N-monomethyl-L-arginine. Anesthesiology 1996;85(Suppl):A811.
11. Merrett RA, Thompson CW, Webb FW. In vitro degradation of atracurium in human plasma. Br J Anaesth 1983;55:61-6.
12. Kobzik L, Reid MB, Bredt DS, Stamler JS. Nitric oxide in skeletal muscle. Nature 1994;372:546-8.
13. Ribera J, Marsal J, Casanovas A, et al. Nitric oxide synthase in rat neuromuscular junctions and in nerve terminals of Torpedo electric organ: its role as regulator of acetylcholine release. J Neurosci Res 1998;51:90-102.
14. Kusner LL, Kaminski HJ. Nitric oxide synthase is concentrated at the skeletal muscle endplate. Brain Res 1996;730:238-42.
15. Itoh Y, Okanoue T, Enjo F, et al. Regulation of hepatocyte albumin and alpha 1-acid glycoprotein secretion by monokines, dexamethasone, and nitric oxide synthase pathway: significance of activated liver nonparenchymal cells. Dig Dis Sci 1994;39:851-60.
16. Geller DA, Freeswick PD, Nguyen D, et al. Differential induction of nitric oxide synthase in hepatocytes during endotoxemia and the acute-phase response. Arch Surg 1994;129:165-71.